Early Wednesday, Regeneron Pharmaceuticals (REGN) reported adjusted income of $11.49 per share on $2.97 billion in first-quarter sales. In response, REGN stock rose moderately.
On average, analysts polled by FactSet expected Regeneron to earn $9.68 per share on $2.69 billion in sales. The company's Covid antibody treatment brought in $635.6 million in sales — all outside the U.S. Excluding that product, Regeneron's total sales popped 25% to $2.75 billion.
In the year-earlier period, Regeneron earned $9.89 a share and reported $2.53 billion in sales.
https://www.investors.com/news/technology/regn-stock-regeneron-earnings-q1-2022/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.